Qingdao Vland Biotech INC. (SHA:603739)
China · Delayed Price · Currency is CNY 14.75
-0.53 (-3.47%)
May 12, 2026, 3:00 PM CST
SHA:603739 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,401 | 1,366 | 1,282 | 1,177 | 1,135 | 1,110 |
Other Revenue | - | - | 38.97 | 21.48 | 28.42 | 40.48 |
| 1,401 | 1,366 | 1,321 | 1,199 | 1,163 | 1,151 | |
Revenue Growth (YoY) | 4.23% | 3.44% | 10.16% | 3.07% | 1.07% | 19.85% |
Cost of Revenue | 774 | 754.15 | 728.42 | 648.46 | 662.86 | 620.4 |
Gross Profit | 626.98 | 611.97 | 592.34 | 550.44 | 500.3 | 530.43 |
Selling, General & Admin | 355.81 | 353.16 | 343.98 | 314.46 | 297.58 | 285 |
Research & Development | 140.88 | 139.21 | 118.22 | 110.68 | 102.4 | 100.94 |
Other Operating Expenses | -14.81 | -14.47 | 11.79 | 9.19 | 8.78 | 8.96 |
Operating Expenses | 486.32 | 477.9 | 477.91 | 447.32 | 420.62 | 400.69 |
Operating Income | 140.66 | 134.07 | 114.44 | 103.12 | 79.68 | 129.74 |
Interest Expense | -1.09 | - | -21.88 | -15.22 | -7.17 | -2.12 |
Interest & Investment Income | 1.85 | - | 1.53 | 8 | 3.93 | 7.91 |
Currency Exchange Gain (Loss) | - | - | 0.47 | 0.58 | 3.21 | -1.18 |
Other Non Operating Income (Expenses) | -34.95 | -35.62 | -2.97 | -1.62 | -8.46 | -1.88 |
EBT Excluding Unusual Items | 106.48 | 98.45 | 91.58 | 94.87 | 71.18 | 132.46 |
Gain (Loss) on Sale of Investments | 31.31 | 31.31 | 7.08 | 9.22 | 0.21 | 0.43 |
Gain (Loss) on Sale of Assets | 0.47 | 0.47 | 0.13 | -0.25 | 0.29 | -0.05 |
Asset Writedown | -6.69 | -6.53 | -0.07 | -2.75 | - | - |
Other Unusual Items | - | - | 24.73 | 21.41 | 30.51 | 38.56 |
Pretax Income | 131.56 | 123.71 | 123.44 | 122.5 | 102.19 | 171.4 |
Income Tax Expense | 25.23 | 26.24 | 31.27 | 19.64 | 16.78 | 21.31 |
Earnings From Continuing Operations | 106.33 | 97.47 | 92.17 | 102.86 | 85.41 | 150.1 |
Minority Interest in Earnings | -28.23 | -27.66 | -29.53 | -22.15 | -15.57 | -17.52 |
Net Income | 78.1 | 69.81 | 62.64 | 80.71 | 69.84 | 132.57 |
Net Income to Common | 78.1 | 69.81 | 62.64 | 80.71 | 69.84 | 132.57 |
Net Income Growth | 31.28% | 11.45% | -22.39% | 15.56% | -47.32% | 21.65% |
Shares Outstanding (Basic) | 253 | 249 | 251 | 252 | 249 | 246 |
Shares Outstanding (Diluted) | 253 | 249 | 251 | 252 | 259 | 246 |
Shares Change (YoY) | 2.63% | -0.49% | -0.66% | -2.50% | 5.36% | 8.14% |
EPS (Basic) | 0.31 | 0.28 | 0.25 | 0.32 | 0.28 | 0.54 |
EPS (Diluted) | 0.31 | 0.28 | 0.25 | 0.32 | 0.27 | 0.54 |
EPS Growth | 27.92% | 12.00% | -21.88% | 18.52% | -50.00% | 12.50% |
Free Cash Flow | 71.15 | 33.94 | 90.69 | -62.05 | -246.72 | -404.06 |
Free Cash Flow Per Share | 0.28 | 0.14 | 0.36 | -0.25 | -0.95 | -1.65 |
Dividend Per Share | - | - | 0.100 | 0.100 | 0.100 | 0.160 |
Dividend Growth | - | - | - | - | -37.50% | 11.97% |
Gross Margin | 44.75% | 44.80% | 44.85% | 45.91% | 43.01% | 46.09% |
Operating Margin | 10.04% | 9.81% | 8.66% | 8.60% | 6.85% | 11.27% |
Profit Margin | 5.58% | 5.11% | 4.74% | 6.73% | 6.00% | 11.52% |
Free Cash Flow Margin | 5.08% | 2.48% | 6.87% | -5.18% | -21.21% | -35.11% |
EBITDA | 258.76 | 250.63 | 224.85 | 176.92 | 145.39 | 181.44 |
EBITDA Margin | 18.47% | 18.35% | 17.02% | 14.76% | 12.50% | 15.77% |
D&A For EBITDA | 118.1 | 116.56 | 110.41 | 73.79 | 65.71 | 51.7 |
EBIT | 140.66 | 134.07 | 114.44 | 103.12 | 79.68 | 129.74 |
EBIT Margin | 10.04% | 9.81% | 8.66% | 8.60% | 6.85% | 11.27% |
Effective Tax Rate | 19.18% | 21.21% | 25.33% | 16.03% | 16.42% | 12.43% |
Revenue as Reported | 34.85 | - | 1,321 | 1,199 | 1,163 | 1,151 |
Advertising Expenses | - | - | 7.09 | 6.59 | 5.02 | 5.67 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.